These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8428253)

  • 1. Kinetic considerations in the choice of treatment schedules for neuraxis radiotherapy.
    Wheldon TE; O'Donoghue JA; Barrett A
    Br J Radiol; 1993 Jan; 66(781):61-6. PubMed ID: 8428253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An innovative method for neuraxis radiotherapy using partial transmission block technique.
    Plowman PN; Doughty D
    Br J Radiol; 1991 Jul; 64(763):603-7. PubMed ID: 1908345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy.
    McAneney H; O'Rourke SF
    Phys Med Biol; 2007 Feb; 52(4):1039-54. PubMed ID: 17264369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation of the optimum dose per fraction from the linear quadratic model.
    Jones B; Tan LT; Dale RG
    Br J Radiol; 1995 Aug; 68(812):894-902. PubMed ID: 7551788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An historical survey of radiobiology and radiotherapy with fast neutrons.
    Field SB
    Curr Top Radiat Res Q; 1976 Jan; 11(1):1-86. PubMed ID: 1106959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-uniform dwell times in line source high dose rate brachytherapy: physical and radiobiological considerations.
    Jones B; Tan LT; Freestone G; Bleasdale C; Myint S; Littler J
    Br J Radiol; 1994 Dec; 67(804):1231-7. PubMed ID: 7874423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment of central nervous system tumours.
    Jones B; Grant W
    Clin Oncol (R Coll Radiol); 2014 Jul; 26(7):407-18. PubMed ID: 24793503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiobiological philosophy of current U.S. neutron trials.
    Withers HR
    Strahlenther Onkol; 1989 Apr; 165(4):294-7. PubMed ID: 2652356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy dose-fractionation schedules. Hyperfractionation and accelerated treatment regimens.
    Freeman CR; Lehnert S
    Neurol Clin; 1991 May; 9(2):351-62. PubMed ID: 1944104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discussion of radiobiological factors operating in low dose rate irradiation.
    Burgers JM
    Radiol Clin (Basel); 1978; 47(2):132-8. PubMed ID: 625553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
    Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical derivation of optimal treatment schedules for the radiotherapy of human tumours. Fractionated irradiation of exponentially growing tumours.
    Wheldon TE; Kirk J
    Br J Radiol; 1976 May; 49(581):441-9. PubMed ID: 949578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proposed figure of merit for the assessment of unscheduled treatment interruptions.
    Dale RG; Sinclair JA
    Br J Radiol; 1994 Oct; 67(802):1001-7. PubMed ID: 8000824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiobiological considerations in the design of clinical trials.
    Bentzen SM
    Radiother Oncol; 1994 Jul; 32(1):1-11. PubMed ID: 7938673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma.
    Fowler JF; Ritter MA
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):521-9. PubMed ID: 7751194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiobiological rationale of neutron radiotherapy].
    Masuda K; Aramaki R; Sasaki H; Cho T; Yoshinaga H
    Fukuoka Igaku Zasshi; 1986 Dec; 77(12):641-50. PubMed ID: 3549497
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiobiological rationale for compensation for gaps in radiotherapy regimens by post-gap acceleration of fractionation.
    Wheldon TE; Barrett A
    Br J Radiol; 1990 Feb; 63(746):114-9. PubMed ID: 2310903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.
    Wyatt RM; Jones BJ; Dale RG
    Br J Radiol; 2008 Jul; 81(967):549-63. PubMed ID: 18378526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry in nuclear medicine therapy: radiobiology application and results.
    Strigari L; Benassi M; Chiesa C; Cremonesi M; Bodei L; D'Andrea M
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):205-21. PubMed ID: 21386791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of the potential doubling time (Tpot) measured by flow cytometry].
    Dubray B; Maciorowsky Z; Cosset JM; Terry NH
    Bull Cancer; 1995; 82(5):331-8. PubMed ID: 7626840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.